References
- Chang TK, Gonzalenz FJ, Waxman DJ. (1994). Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437–42
- Draper AJ, Hammock BD. (2000). Identification of CYP2C9 as a human liver microsomal linoleic acid epoxygenase. Arch Biochem Biophys 376:199–205
- Ghosal A, Yuan Y, Tong W, et al. (2011). Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 39:510–21
- Guengerich FP. (2008). Cytochrome P450 and chemical toxicology. Chem Res Toxicol 21:70–83
- Harper TW, Brassil PJ. (2008). Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J 10:200–7
- Hesse LM, He P, Krishnaswamy S, et al. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225–38
- Jancova P, Anzenbacherova E, Papouskova B, et al. (2007). Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos 35:2035–9
- Komen JC, Wander RJA. (2006). Identification of the cytochrome P450 enzymes responsible for the w-hydroxylation of phytanic acid. FEBS Lett 580:3794–8
- Lade JM, Avery LB, Bumpus NN. (2013). Human biotransformation of the Nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother 57:5067–79
- Lin L, Xie C, Gao Z, et al. (2014). Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome p450s and epoxide hydrolase in its biotransformation. Drug Metab Dispos 42:872–4
- Lu AYH, Wang RW, Lin JH. (2008). Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. AAPS J 10:200–7
- Margolis JM, Obach RS. (2003). Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31:606–11
- Nebot N, Crettol S, d’Esposito F, et al. (2010). Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 161:1059–69
- Nirogi R, Kandikere V, Palacharla RC, et al. (2014). Identification of suitable and selective inhibitor towards aldehyde oxidase catalyzed reactions. Xenobiotica 44:197–204
- Preissner SC, Hoffmann MF, Preissner R, et al. (2013). Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One 8:1–12
- Svensson US, Ashton M. (1999). Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 48:528–35
- Tran TH, Von Moltke LL, Venkatakrishnan K, et al. (2002). Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A4 inhibitors. Drug Metab Dispos 30:1441–5
- Tuvesson H, Hallin I, Persson R, et al. (2005). Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab Dispos 33:866–72
- Walsky RL, Obach RS. (2007). A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1′,1′′-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab Dispos 35:2053–9
- Walsky RL, Obach RS, Gaman EA, et al. (2005). Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413–18
- Wang L, Christopher LJ, Cui D, et al. (2008). Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 36:1828–39
- Wang L, Zhang D, Raghavan N, et al. (2010). In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition and induction studies. Drug Metab Dispos 38:448–58
- Williams JA, Hurst SI, Bauman J, et al. (2003). Reaction phenotyping in drug discovery: moving forward with confidence? Curr Drug Metab 4:527–34
- Yanakakis LJ, Bumpus NN. (2012). Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos 40:803–14
- Zhang H, Davis CD, Sing MW, Rodrigues AD. (2007). Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667–87
- Zhou SF. (2009). Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48:689–723
- Zhou SF, Liu JP, Chowbay B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295
- Zhu Y, Wang F, Li Q, et al. (2014). Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos 42:245–9